Anja Sandek

Dr. Anja Sandek


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in International Journal of Cardiology
Verified
Journal Article
Open access
TBTarek Bekfani
Tarek Bekfani
PPPierpaolo Pellicori
Pierpaolo Pellicori
Daniel A. MorrisDaniel A. Morris
Daniel A. Morris
NENicole Ebner
Nicole Ebner
MVMiroslava Valentova
Miroslava Valentova
Stephan Von HaehlingStephan Von Haehling
Stephan Von Haehling
To describe the prevalence of sarcopenia in ambulatory patients with heart failure with preserved ejection fraction (HFpEF) and its relation to reduced exercise capacity, muscle strength, and quality of life (QoL). A total of 117 symptomatic outpatients with HFpEF were prospectively enrolled in Germany, England, and Slovenia as part of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Appendicular skeletal muscle (ASM) mass (the sum of muscle mass in both arms and legs) was assessed by DEXA. Echocardiography, 6-minute walk testing (6-MWT), muscle strength assessment, spiroergometry and QoL evaluation using EQ-5D Questionnaire were performed. Sarcopenia was defined as ASM 2 standard deviations below the mean of a healthy reference group aged 18-40years. Patients were divided into 3 groups according to the E/e' value: ≤8, 9-14, and ≥15. Sarcopenia was detected in 19.7% of all patients. These patients performed worse during 6-MWT (404±116 vs. 307±145m, p=0.003) and showed lower absolute peak oxygen consumption (1579±474 vs. 1211±442mL/min, p15 (p<0.05). Higher values of muscle strength/ASM were associated with a better QoL (r=0.5, p<0.0005). Logistic regression showed ASM to be independently associated with reduced distance walked during the 6-MWT adjusted for NYHA, height, left atrium diameter, ferritin and forced expiratory volume in 1s (FEV1) (odds ratio 1.2, p=0.02). Sarcopenia affects a clinically relevant proportion of patients with HFpEF. Low ASM is strongly linked to reduced muscle strength, exercise capacity and QoL in these patients.

6 May 2015 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
NENicole Ebner
Nicole Ebner
VSVeronika Sliziuk
Veronika Sliziuk
NSNadja Scherbakov
Nadja Scherbakov
ASAnja Sandek
Anja Sandek
Purpose As life expectancy increases, muscle wasting is becoming a more and more important public health problem. This review summarizes the current knowledge of pathophysiological mechanisms underlying muscle loss in ageing and chronic diseases such as heart failure and discusses evolving interventional strategies. Recent findings Loss of skeletal muscle mass and strength is a common phenomenon in a wide variety of disorders associated with ageing and morbidity‐associated catabolic conditions such as chronic heart failure. Muscle wasting in ageing but otherwise healthy human beings is referred to as sarcopenia. Unlike cachexia in advanced stages of chronic heart failure, muscle wasting per se is not necessarily associated with weight loss. In this review, we discuss pathophysiological mechanisms underlying muscle loss in sarcopenia and cachexia, highlight similarities and differences of both conditions, and discuss therapeutic targets and possible treatments, such as exercise training, nutritional support, and drugs. Candidate drugs to treat muscle wasting disease include myostatin antagonists, ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors. Summary Present approaches to muscle wasting disease include exercise training, nutritional support, and drugs, although particularly the latter remain currently restricted to clinical studies. Optimizing skeletal muscle mass and function in ageing and chronic illness including heart failure is one of the chapters that are far from finished and gains future potential for new therapeutic interventions to come.

25 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DJDr. Nadja Jauert
Dr. Nadja Jauert
ASAnja Sandek
Anja Sandek
MVMiroslava Valentova
Miroslava Valentova
AMAntje Mayer
Antje Mayer
Stephan Von HaehlingStephan Von Haehling
Stephan Von Haehling
Wolfram Doehner, MD, PhDWolfram Doehner, MD, PhD
Wolfram Doehner, MD, PhD
(1) Introduction: Iron deficiency (ID) contributes to impaired functional performance and reduced quality of life in patients with chronic illnesses. The role of ID in stroke is unclear. The aim of this prospective study was to evaluate the prevalence of ID and to evaluate its association with long-term functional outcome in patients with ischemic stroke. (2) Patients and Methods: 140 patients (age 69 ± 13 years, BMI 27.7 ± 4.6 kg/m², mean ± SD) admitted to a university hospital stroke Unit, with acute ischemic stroke of the middle cerebral artery were consecutively recruited to this observational study. Study examinations were completed after admission (3 ± 2 days after acute stroke) and at one-year follow up (N = 64, 382 ± 27 days after stroke). Neurological status was evaluated according to the National Institute of Health Stroke Scale (NIHSS) and the modified Rankin scale (mRS). Muscle isometric strength of the non-affected limb was assessed by the maximum handgrip test and knee extension leg test. ID was diagnosed with serum ferritin levels ≤ 100 µg/L (ID Type I) or 100–300 µg/L if transferrin saturation (TSAT) < 20% (ID Type II). (3) Results: The prevalence of ID in acute stroke patients was 48% (N = 67), with about two-thirds of patients (N = 45) displaying ID Type I and one-third (N = 22) Type II. Handgrip strength (HGS) and quadriceps muscle strength were reduced in patients with ID compared to patients without ID at baseline (HGS: 26.5 ± 10.4 vs. 33.8 ± 13.2 kg, p < 0.001 and quadriceps: 332 ± 130 vs. 391 ± 143 N, p = 0.06). One year after stroke, prevalence of ID increased to 77% (p = 0.001). While an improvement of HGS was observed in patients with normal iron status, patients with ID had no improvement in HGS difference (4.6 ± 8.3 vs. −0.7 ± 6.5 kg, p < 0.05). Patients with ID remained with lower HGS compared to patients with normal iron status (28.2 ± 12.5 vs. 44.0 ± 8.6 kg, p < 0.0001). (4) Conclusions: Prevalence of ID was high in patients after acute stroke and further increased one year after stroke. ID was associated with lower muscle strength in acute stroke patients. In patients with ID, skeletal muscle strength did not improve one year after stroke.

12 March 2023 in ESC Heart Failure
Verified
Journal Article
Open access
CGChristoph Gertler
Christoph Gertler
NJNadja Jauert
Nadja Jauert
PFPatrick Freyhardt
Patrick Freyhardt
MVMiroslava Valentova
Miroslava Valentova
SASven Christopher Aland
Sven Christopher Aland
ASAnja Sandek
Anja Sandek
Aims: Intravenous iron therapy (IVIT) is known to improve functional status in chronic heart failure (CHF) patients. The exact mechanism is not completely understood. We correlated magnetic resonance imaging (MRI) patterns of T2* iron signal in various organs to systemic iron and exercise capacity (EC) in CHF before and after IVIT. Methods and results: We prospectively analysed 24 patients with systolic CHF for T2* MRI pattern of the left ventricle (LV), small and large intestines, spleen, liver, skeletal muscle, and brain for iron. In 12 patients with iron deficiency (ID), we restored iron deficit by IVIT using ferric carboxymaltose. The effects after 3 months were analysed by spiroergometry and MRI. Patients with vs. without ID showed lower blood ferritin, haemoglobin (76 ± 63 vs. 196 ± 82 μg/L and 12.3 ± 1.1 vs. 14.2 ± 1.1 g/dL, all P < 0.002), and in trend a lower transferrin saturation (TSAT) (19.1 [13.1; 28.2] vs. 25.1 [21.3; 29.1] %, P = 0.05). Spleen and liver iron was lower as expressed by higher T2* value (71.8 [66.4; 93.1] vs. 36.9 [32.9; 51.7] ms, P < 0.002 and 33.5 ± 5.9 vs. 28.8 ± 3.9 ms, and P < 0.03). There was a strong trend for a lower cardiac septal iron content in ID (40.6 [33.0; 57.3] vs. 33.7 [31.3; 40.2] ms, P = 0.07). After IVIT, ferritin, TSAT, and haemoglobin increased (54 [30; 104] vs. 235 [185; 339] μg/L, 19.1 [13.1; 28.2] vs. 25.0 [21.0; 33.7] %, 12.3 ± 1.1 vs. 13.3 ± 1.3 g/L, all P < 0.04). Peak VO2 improved (18.2 ± 4.2 vs. 20.9 ± 3.8 mL/min/kg−1, P = 0.05). Higher peak VO2 at anaerobic threshold was associated with higher blood ferritin, reflecting higher metabolic exercise capacity after therapy (r = 0.9, P = 0.0009). Increase in EC was associated with haemoglobin increase (r = 0.7, P = 0.034). LV iron increased by 25.4% (48.5 [36.2; 64.8] vs. 36.2 [32.9; 41.9] ms, P < 0.04). Spleen and liver iron increased by 46.4 and 18.2%, respectively (71.8 [66.4; 93.1] vs. 38.5 [22.4; 76.9] ms, P < 0.04 and 33.5 ± 5.9 vs. 27.4 ± 8.6 ms, P < 0.007). Iron in skeletal muscle, brain, intestine, and bone marrow remained unchanged (29.6 [28.6; 31.2] vs. 30.4 [29.7; 30.7] ms, P = 0.7, 81.0 ± 6.3 vs. 82.9 ± 9.9 ms, P = 0.6, 34.3 ± 21.4 vs. 25.3 ± 14.1 ms, P = 0.2, 9.4 [7.5; 21.8] vs. 10.3 [6.7; 15.7] ms, P = 0.5 and 9.8 ± 1.5 vs. 13.7 ± 8.9 ms, P = 0.1). Conclusions: CHF patients with ID showed lower spleen, liver, and in trend lower cardiac septal iron. After IVIT, iron signal of the left ventricle as well as spleen and liver increased. Improvement in EC was associated with increase in haemoglobin after IVIT. In ID, liver, spleen, and brain but not heart iron were associated with markers of systemic ID.

28 June 2024 in Global Cardiology
Verified
Journal Article
Open access
PDF file
SASven Christopher Aland
Sven Christopher Aland
CGChristoph Gertler
Christoph Gertler
HBHannah Leonie Bräunig
Hannah Leonie Bräunig
TSTimo Schröder
Timo Schröder
FEFrank Edelmann
Frank Edelmann
ASAnja Sandek
Anja Sandek
Background: Iron deficiency (ID) is a common comorbidity in symptomatic heart failure (HF). It is associated with lower exercise capacity, anemia and poor quality of life and has proven to be a successful therapeutic target. In asymptomatic heart failure (NYHA 1) with reduced ejection fraction (HFrEF) however, prevalence of ID and its impact on exercise capacity, anemia and depressive symptoms are unknown.Methods: We analyzed 364 asymptomatic HFrEF patients for ID, ID-associated impairment of exercise capacity, anemia, inflammation, ventricular overload and depressive symptoms. Exercise capacity was measured by 6-minute walk test (6 MWT), peak oxygen consumption per kg bodyweight (peak VO2) and breathing efficiency (VE-VCO2 slope). ID was defined as ferritin <100 µg/L or ferritin 100-299 µg/L with transferrin saturation (TSAT) 5 mg/L. Depressive symptoms were diagnosed by Hospital Anxiety and Depression-Scale (HADS-D) score ≥11 and Patient Health Questionnaire 9 (PHQ-9) score≥10. Results: Prevalences were 36.5% (29.3% absolute, 7.2% functional) for ID, 11% for anemia, 15.3% for inflammation and 6.5% (HADS-D) and 9.8% (PHQ-9) for depressive symptoms. The latter were similar in patients with/without ID (6.7% vs. 6.4%, p=0.46). Patients with ID had lower breathing efficiency (26.8±6.4 vs. 25.2±6.1, p=0.015), lower 6 MW distance (557 m±99 vs. 577 m±84, p=0.030), higher NT-pro BNP (545 ng/l [201; 1226] vs. 428 ng/L [195; 783], p=0.047), more often anemia (15.9% vs. 8.2%, p=0.015) and inflammation for functional ID (8/25 vs. 13/101, p=0.015). Patients with a TSAT25% (565±90 vs. 581±74 vs. 589±86 ms, p=0.003). In univariate regression models, we found higher sTfR to be associated with anemia (r=0.122, p<0.015), inflammation (r=0.118, p<0.02), ventricular overload (r=0.202, p<0.001) and lower exercise capacity in form of 6 MW distance (r=-0.138, p=0.007), which is similar to ID by ESC definition. In multivariable regression, only NT-pro BNP and in trend ID by ESC definition independently predicted lower breathing efficiency (p1400 ng/L yielded 90% specificity for ID in ROC analysis. Conclusions: ID is a common comorbidity already in asymptomatic HFrEF patients. In a multivariable model, NT-pro BNP and in trend ID independently predicted lower breathing efficiency. NT-pro BNP>1400 ng/L yielded 90% specificity for ID. An association of ID with worsening of breathing efficiency and transition to higher NYHA classes should be subject of further studies.

27 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAnja Sandek
Anja Sandek
CGChristoph Gertler
Christoph Gertler
MVMiroslava Valentova
Miroslava Valentova
DJDr. Nadja Jauert
Dr. Nadja Jauert
MWManuel Wallbach
Manuel Wallbach
HVHans-Dieter Volk
Hans-Dieter Volk
Background: Cardiac cachexia (CC) in chronic heart failure with reduced ejection fraction (HFrEF) is characterized by catabolism and inflammation predicting poor prognosis. Levels of responsible transcription factors like signal transducer and activator of transcription (STAT)1, STAT3, suppressor of cytokine signaling (SOCS)1 and SOCS3 in peripheral blood cells (PBC) are underinvestigated in CC. Expression of mediators was related to patients’ functional status, body composition (BC) and metabolic gene expression in skeletal muscle (SM). Methods: Gene expression was quantified by qRT-PCR in three cohorts: non-cachectic patients (ncCHF, n = 19, LVEF 31 ± 7%, BMI 30.2 ± 5.0 kg/m2), cachectic patients (cCHF; n = 18, LVEF 27 ± 7%, BMI 24.3 ± 2.5 kg/m2) and controls (n = 17, LVEF 70 ± 7%, BMI 27.6 ± 4.6 kg/m2). BC was assessed by dual-energy X-ray absorptiometry. Blood inflammatory markers were measured. We quantified solute carrier family 2 member 4 (SLC2A4) and protein degradation by expressions of proteasome 20S subunit beta 2 and calpain-1 catalytic subunit in SM biopsies. Results: TNF and IL-10 expression was higher in cCHF than in ncCHF and controls (all p < 0.004). cCHF had a lower fat mass index (FMI) and lower fat-free mass index (FFMI) compared to ncCHF and controls (p < 0.05). STAT1 and STAT3 expression was higher in cCHF vs. ncCHF or controls (1.1 [1.6] vs. 0.8 [0.9] vs. 0.9 [1.1] RU and 4.6 [5.5] vs. 2.5 [4.8] vs. 3.0 [4.2] RU, all ANOVA-p < 0.05). The same applied for SOCS1 and SOCS3 expression (1.1 [1.5] vs. 0.4 [0.4] vs. 0.4 [0.5] and 0.9 [3.3] vs. 0.4 [1.1] vs. 0.8 [0.9] RU, all ANOVA-p < 0.04). In cCHF, higher TNF and STAT1 expression was associated with lower FMI (r = 0.5, p = 0.053 and p < 0.05) but not with lower FFMI (p > 0.4). In ncCHF, neither cytokine nor STAT/SOCS expression was associated with BC (all p > 0.3). SLC2A4 was upregulated in SM of cCHF vs. ncCHF (p < 0.03). Conclusions: Increased STAT1, STAT3, SOCS1 and SOCS3 expression suggests their involvement in CC. In cCHF, higher TNF and STAT-1 expression in PBC were associated with lower FMI. Increased SLC2A4 in cachectic SM biopsies indicates altered glucose metabolism.